SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biogen
BIIB 159.65+2.2%3:59 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Harold Engstrom who wrote (793)12/24/1998 11:41:00 AM
From: Vector1  Read Replies (3) of 1686
 
Harold,
This whole Vincent /Tobin situation is bizare.

Fundamentally the company has not changed. Right now I would sit tight or be a buyer.
Here are my reasons:
I don't sell a stock I have a large gain in unless I think it is over valued by more than 10%. I take taxes on into consideration. I think BGEN is fairly valued at $75-90.
I think the company will blow away analyst estimates in for the fourth quarter. They clearly have been saving for a rainy day by undereporting revenue. Good companies do this. VIncent will want the first couple of quarters where he is back at the helm to be very strong and they have the ability to do that. I intend to hold until the stock hits $90 which I believe that it will do in by mid Jan. Then I will sell covered calls at $95to 100 with a mid year expiration. With the volitility in the stock it allows me to lock in a nice addtional return without having to sell the stock and pay taxes during the annual summer biotech slump. I don't think we will see data on anti CD 40 until the Fourth Quarter.

Happy Holidays.
V1
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext